{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T22:45:15Z","timestamp":1786488315755,"version":"build-2736575974"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"National Science Technology Council of Taiwan","award":["111\u20132314-B-075A-001-MY3"],"award-info":[{"award-number":["111\u20132314-B-075A-001-MY3"]}]},{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"publisher","award":["1126801C"],"award-info":[{"award-number":["1126801C"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Biologic therapies for skin psoriasis (PsO) have been linked to a lower risk of developing psoriatic arthritis (PsA), but their efficacy across different mechanisms of action remains to be fully explored. This study aimed to compare PsA risk in PsO patients prescribed IL-23 inhibitors (IL23i) vs IL-17 inhibitors (IL17i).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study utilized the TriNetX database to categorize adult PsO patients into two cohorts: those newly prescribed IL23i (without IL17i exposure) and those newly prescribed IL17i (without IL23i exposure). Patients with a history of PsA or previous use of anti-TNF-\u03b1 or anti-IL-12\/23 agents were excluded. A total of 5490 patients, matched 1:1 by propensity scores, were analysed for PsA risk using hazard ratios (HR) from Cox regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The 5-year cumulative incidence of PsA was significantly lower in IL23i users compared with IL17i users (11.68% vs 19.94%; P\u2009&amp;lt;\u20090.001). IL23i treatment was associated with a reduced PsA risk (HR 0.475; 95% CI: 0.382, 0.590). This reduced risk persisted across various subgroups defined by age, sex, race, PsO subtypes, obesity and elevated inflammatory markers. Similar results were observed in individual drug comparisons, with lower risks for guselkumab vs secukinumab (0.480; 0.358, 0.645) and ixekizumab (0.698; 0.509, 0.956), risankizumab vs secukinumab (0.433; 0.306, 0.612) and ixekizumab (0.504; 0.347, 0.732), and tildrakizumab vs secukinumab (0.339, 0.131, 0.875). The comparison of tildrakizumab vs ixekizumab (0.451; 0.171, 1.191) also suggested a lower risk but was not statistically significant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PsO patients treated with IL23i had a lower subsequent PsA risk compared with those treated with IL17i.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf489","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T12:14:00Z","timestamp":1760616840000},"source":"Crossref","is-referenced-by-count":5,"title":["Psoriatic arthritis risk in psoriasis patients receiving anti-IL-23\n                    <i>vs<\/i>\n                    anti-IL-17: comparison of drug classes and individual agents"],"prefix":"10.1093","volume":"65","author":[{"given":"Teng-Li","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Dermatology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation , Chiayi,","place":["Taiwan"]},{"name":"Ph.D. Program of Interdisciplinary Medicine, National Yang Ming Chiao Tung University , Taipei,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hsuan","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Chung Shan Medical University Hospital , Taichung,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Sheng","family":"Fan","sequence":"additional","affiliation":[{"name":"Division of Chest Medicine, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation , Chiayi,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Kuei","family":"Juan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Taichung Veterans General Hospital , Taichung,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ju","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Taichung Veterans General Hospital , Taichung,","place":["Taiwan"]},{"name":"Department of Post-Baccalaureate Medicine, National Chung-Hsing University , Taichung,","place":["Taiwan"]},{"name":"Faculty of Medicine and Institute of Clinical Medicine, National Yang Ming Chiao Tung University , Taipei,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Ying","family":"Wu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Institute of Clinical Medicine, National Yang Ming Chiao Tung University , Taipei,","place":["Taiwan"]},{"name":"Institute of Biomedical Informatics, National Yang Ming Chiao Tung University , Taipei,","place":["Taiwan"]},{"name":"Division of Translational Research, Taipei Veterans General Hospital , Taipei,","place":["Taiwan"]},{"name":"College of Public Health, China Medical University , Taichung,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"2026020205373796600_keaf489-B1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies","volume":"80","author":"Alinaghi","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2026020205373796600_keaf489-B2","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/art.39494","article-title":"The incidence and risk factors for psoriatic arthritis in patients with psoriasis: a prospective cohort Study","volume":"68","author":"Eder","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2026020205373796600_keaf489-B3","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.jaad.2021.09.019","article-title":"Incidence and prevalence of psoriatic arthritis in patients with psoriasis stratified by psoriasis disease severity: retrospective analysis of an electronic health records database in the United States","volume":"86","author":"Merola","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2026020205373796600_keaf489-B4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41584-019-0175-0","article-title":"Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition","volume":"15","author":"Scher","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"2026020205373796600_keaf489-B5","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"2026020205373796600_keaf489-B6","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"2026020205373796600_keaf489-B7","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/annrheumdis-2021-219961","article-title":"Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis","volume":"81","author":"Gisondi","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2026020205373796600_keaf489-B8","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/annrheumdis-2021-220865","article-title":"Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis","volume":"81","author":"Acosta Felquer","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2026020205373796600_keaf489-B9","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/art.41946","article-title":"Incidence of psoriatic arthritis among patients receiving biologic treatments for psoriasis: a nested case-control study","volume":"74","author":"Rosenthal","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2026020205373796600_keaf489-B10","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1093\/rheumatology\/keae257","article-title":"Treatment of psoriasis with different classes of biologics reduces the likelihood of peripheral and axial psoriatic arthritis development","volume":"64","author":"Floris","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026020205373796600_keaf489-B11","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s40744-024-00680-3","article-title":"From psoriasis to psoriatic arthritis: decoding the impact of treatment modalities on the prevention of psoriatic arthritis","volume":"11","author":"Watad","year":"2024","journal-title":"Rheumatol Ther"},{"key":"2026020205373796600_keaf489-B12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/annrheumdis-2021-221255","article-title":"Intercepting psoriatic arthritis in patients with psoriasis: buy one get one free?","volume":"81","author":"McGonagle","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2026020205373796600_keaf489-B13","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/S2665-9913(23)00034-6","article-title":"Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study","volume":"5","author":"Singla","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"2026020205373796600_keaf489-B14","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.jaad.2024.07.1473","article-title":"Interleukin 23 versus interleukin 12\/23 inhibitors on preventing incidental psoriatic arthritis in patients with psoriasis? A real-world comparison from the TriNetX Global Collaborative Network","volume":"91","author":"Tsai","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2026020205373796600_keaf489-B15","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","article-title":"Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis","volume":"156","author":"Armstrong","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2026020205373796600_keaf489-B16","first-page":"CD011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"7","author":"Sbidian","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"2026020205373796600_keaf489-B17","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/pds.3447","article-title":"Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996-2009","volume":"22","author":"Asgari","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"2026020205373796600_keaf489-B18","doi-asserted-by":"crossref","first-page":"e98024","DOI":"10.1371\/journal.pone.0098024","article-title":"Validity of diagnostic codes and prevalence of physician-diagnosed psoriasis and psoriatic arthritis in southern Sweden\u2014a population-based register study","volume":"9","author":"L\u00f6fvendahl","year":"2014","journal-title":"PLoS One"},{"key":"2026020205373796600_keaf489-B19","doi-asserted-by":"crossref","first-page":"115","DOI":"10.5021\/ad.2020.32.2.115","article-title":"Validity of diagnostic codes for identification of psoriasis patients in Korea","volume":"32","author":"Ham","year":"2020","journal-title":"Ann Dermatol"},{"key":"2026020205373796600_keaf489-B20","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jclinepi.2016.12.001","article-title":"Criteria for use of composite end points for competing risks-a systematic survey of the literature with recommendations","volume":"82","author":"Manja","year":"2017","journal-title":"J Clin Epidemiol"},{"key":"2026020205373796600_keaf489-B21","doi-asserted-by":"crossref","first-page":"e1004591","DOI":"10.1371\/journal.pmed.1004591","article-title":"Cardiovascular disease risk in patients with psoriasis receiving biologics targeting TNF-\u03b1, IL-12\/23, IL-17, and IL-23: a population-based retrospective cohort study","volume":"22","author":"Lin","year":"2025","journal-title":"PLoS Med"},{"key":"2026020205373796600_keaf489-B22","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1136\/annrheumdis-2021-220761","article-title":"Does biologic therapy impact the development of PsA among patients with psoriasis?","volume":"81","author":"Meer","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2026020205373796600_keaf489-B23","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1084\/jem.20030896","article-title":"Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation","volume":"198","author":"Murphy","year":"2003","journal-title":"J Exp Med"},{"key":"2026020205373796600_keaf489-B24","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41584-021-00706-y","article-title":"Does psoriasis treatment affect PsA development?","volume":"17","author":"Merola","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"2026020205373796600_keaf489-B25","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med"},{"key":"2026020205373796600_keaf489-B26","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"2026020205373796600_keaf489-B27","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1002\/art.38638","article-title":"interleukin-23 mediates the intestinal response to microbial beta-1,3-glucan and the development of spondyloarthritis pathology in SKG mice","volume":"66","author":"Benham","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2026020205373796600_keaf489-B28","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3389\/fimmu.2018.01550","article-title":"The Initiation, but not the persistence, of experimental spondyloarthritis is dependent on interleukin-23 signaling","volume":"9","author":"van Tok","year":"2018","journal-title":"Front Immunol"},{"key":"2026020205373796600_keaf489-B29","doi-asserted-by":"crossref","first-page":"eabq3254","DOI":"10.1126\/sciimmunol.abq3254","article-title":"Local IL-23 is required for proliferation and retention of skin-resident memory TH17 cells","volume":"7","author":"Whitley","year":"2022","journal-title":"Sci Immunol"},{"key":"2026020205373796600_keaf489-B30","doi-asserted-by":"crossref","first-page":"1346757","DOI":"10.3389\/fmed.2024.1346757","article-title":"From PsO to PsA: the role of TRM and Tregs in psoriatic disease, a systematic review of the literature","volume":"11","author":"Lob\u00e3o","year":"2024","journal-title":"Front Med (Lausanne)."},{"key":"2026020205373796600_keaf489-B31","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/j.jid.2021.01.005","article-title":"Differential changes in inflammatory mononuclear phagocyte and T-cell profiles within psoriatic skin during treatment with Guselkumab vs. Secukinumab","volume":"141","author":"Mehta","year":"2021","journal-title":"J Invest Dermatol"},{"key":"2026020205373796600_keaf489-B32","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.4049\/jimmunol.1600383","article-title":"T cell-independent mechanisms associated with neutrophil extracellular trap formation and selective autophagy in IL-17A-mediated epidermal hyperplasia","volume":"197","author":"Suzuki","year":"2016","journal-title":"J Immunol"},{"key":"2026020205373796600_keaf489-B33","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1172\/JCI133159","article-title":"KLK6 expression in skin induces PAR1-mediated psoriasiform dermatitis and inflammatory joint disease","volume":"130","author":"Billi","year":"2020","journal-title":"J Clin Invest"},{"key":"2026020205373796600_keaf489-B34","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/nrrheum.2018.17","article-title":"Proteinases and their receptors in inflammatory arthritis: an overview","volume":"14","author":"Oikonomopoulou","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2026020205373796600_keaf489-B35","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"2026020205373796600_keaf489-B36","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjd.19341","article-title":"Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial","volume":"184","author":"Warren","year":"2021","journal-title":"Br J Dermatol"},{"key":"2026020205373796600_keaf489-B37","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40265-024-02028-1","article-title":"Drug survival of IL-17 and IL-23 inhibitors for psoriasis: a systematic review and meta-analysis","volume":"84","author":"Thomas","year":"2024","journal-title":"Drugs"},{"key":"2026020205373796600_keaf489-B38","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s13555-018-0266-x","article-title":"Clinical and genetic risk factors associated with psoriatic arthritis among patients with psoriasis","volume":"8","author":"Yan","year":"2018","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026020205373796600_keaf489-B39","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s13075-021-02545-4","article-title":"Clinical, laboratory, and genetic markers for the development or presence of psoriatic arthritis in psoriasis patients: a systematic review","volume":"23","author":"Mulder","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2026020205373796600_keaf489-B40","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/bjd\/ljac040","article-title":"Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials","volume":"188","author":"Langley","year":"2023","journal-title":"Br J Dermatol"},{"key":"2026020205373796600_keaf489-B41","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/14712598.2021.1849133","article-title":"Comparison of short- and long-term effectiveness of ixekizumab and secukinumab in real-world practice","volume":"21","author":"Caldarola","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"2026020205373796600_keaf489-B42","doi-asserted-by":"crossref","first-page":"105833","DOI":"10.1016\/j.jbspin.2024.105833","article-title":"Early methotrexate treatment for psoriatic arthritis prevention in psoriasis patients\u2014a retrospective cohort study","volume":"92","author":"Bar","year":"2025","journal-title":"Joint Bone Spine."}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf489\/64739214\/keaf489.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/1\/keaf489\/64739214\/keaf489.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/1\/keaf489\/64739214\/keaf489.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T10:37:50Z","timestamp":1770028670000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/doi\/10.1093\/rheumatology\/keaf489\/8292703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,8]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf489","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,10,17]]},"article-number":"keaf489"}}